{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:54:31Z","timestamp":1793235271071,"version":"4.5.0"},"reference-count":24,"publisher":"American Veterinary Medical Association (AVMA)","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>Feline hypertrophic cardiomyopathy (HCM) remains a disease with little therapeutic advancement. Rapamycin modulates the mTOR pathway, preventing and reversing cardiac hypertrophy in rodent disease models. Its use in human renal allograft patients is associated with reduced cardiac wall thickness. We sought to evaluate the effects of once-weekly delayed-release (DR) rapamycin over 6 months on echocardiographic, biochemical, and biomarker responses in cats with subclinical, nonobstructive HCM.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>ANIMALS<\/jats:title>\n<jats:p>43 client-owned cats with subclinical HCM.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>METHODS<\/jats:title>\n<jats:p>Cats enrolled in this double-blinded, multicentered, randomized, and placebo-controlled clinical trial were allocated to low- or high-dose DR rapamycin or placebo. Cats underwent physical examination, quality-of-life assessment, blood pressure, hematology, biochemistry, total T4, urinalysis, N-terminal pro-B-type natriuretic peptide, and cardiac troponin I at baseline and days 60, 120, and 180. Fructosamine was analyzed at screening and day 180. Echocardiograms were performed at all time points excluding day 120. Outcome variables were compared using a repeated measures ANCOVA.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS<\/jats:title>\n<jats:p>No demographic, echocardiographic, or clinicopathologic values were significantly different between study groups at baseline, confirming successful randomization. At day 180, the primary study outcome variable, maximum LV myocardial wall thickness at any location, was significantly lower in the low-dose DR rapamycin group compared to placebo (<jats:italic>P<\/jats:italic> = .01). Oral DR rapamycin was well tolerated with no significant differences in adverse events between groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CLINICAL RELEVANCE<\/jats:title>\n<jats:p>Results demonstrate that DR rapamycin was well tolerated and may prevent or delay progressive LV hypertrophy in cats with subclinical HCM. Additional studies are warranted to confirm and further characterize these results.<\/jats:p>\n<\/jats:sec>","DOI":"10.2460\/javma.23.04.0187","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T18:29:16Z","timestamp":1690396156000},"page":"1628-1637","source":"Crossref","is-referenced-by-count":28,"title":["Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trial"],"prefix":"10.2460","volume":"261","author":[{"given":"Joanna L.","family":"Kaplan","sequence":"first","affiliation":[{"name":"Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor N.","family":"Rivas","sequence":"additional","affiliation":[{"name":"Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA"},{"name":"Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley L.","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Grubb","sequence":"additional","affiliation":[{"name":"TriviumVet, Waterford, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"Farrell","sequence":"additional","affiliation":[{"name":"TriviumVet, Waterford, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"TriviumVet, Waterford, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Kennedy","sequence":"additional","affiliation":[{"name":"TriviumVet, Waterford, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina E.","family":"Jauregui","sequence":"additional","affiliation":[{"name":"Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA"},{"name":"Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda E.","family":"Crofton","sequence":"additional","affiliation":[{"name":"Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Van Zile","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa C.","family":"DeFrancesco","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Meurs","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Stern","sequence":"additional","affiliation":[{"name":"Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA"},{"name":"Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"issue":"11","key":"ref1","series-title":"J Feline Med Surg","first-page":"1028","article-title":"The feline cardiomyopathies: 2. hypertrophic cardiomyopathy","volume":"23","author":"Kittleson MD","year":"2021","unstructured":"Kittleson MD, C\u00f4t\u00e9 E. The feline cardiomyopathies: 2. hypertrophic cardiomyopathy. J Feline Med Surg. 2021;23(11):1028-1051. doi:10.1177\/1098612X211020162"},{"issue":"3","key":"ref2","series-title":"J Vet Intern Med","first-page":"1062","article-title":"ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats","volume":"34","author":"Luis Fuentes V","year":"2020","unstructured":"Luis Fuentes V, Abbott J, Chetboul V,  ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats. J Vet Intern Med. 2020;34(3):1062-1077. doi:10.1111\/jvim.15745"},{"issue":"suppl 1","key":"ref3","series-title":"J Vet Cardiol","first-page":"S244","article-title":"Cardiomyopathy prevalence in 780 apparently healthy cats in rehoming centres (the CatScan study)","volume":"17","author":"Payne JR","year":"2015","unstructured":"Payne JR, Brodbelt DC, Luis Fuentes V. Cardiomyopathy prevalence in 780 apparently healthy cats in rehoming centres (the CatScan study). J Vet Cardiol. 2015;17(suppl 1):S244-S257. doi:10.1016\/j.jvc.2015.03.008"},{"issue":"3","key":"ref4","series-title":"J Vet Intern Med","first-page":"930","article-title":"International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: the REVEAL Study","volume":"32","author":"Fox PR","year":"2018","unstructured":"Fox PR, Keene BW, Lamb K,  International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: the REVEAL Study. J Vet Intern Med. 2018;32(3):930-943. doi:10.1111\/jvim.15122"},{"issue":"3","key":"ref5","series-title":"Circ Res","first-page":"489","article-title":"New insights into the role of mTOR signaling in the cardiovascular system","volume":"122","author":"Sciarretta S","year":"2018","unstructured":"Sciarretta S, Forte M, Frati G, Sadoshima J. New insights into the role of mTOR signaling in the cardiovascular system. Circ Res. 2018;122(3):489-505. doi:10.1161\/CIRCRESAHA.117.311147"},{"issue":"12","key":"ref6","series-title":"Circulation","first-page":"1664","article-title":"Rapamycin attenuates load-induced cardiac hypertrophy in mice","volume":"107","author":"Shioi T","year":"2003","unstructured":"Shioi T, McMullen JR, Tarnavski O,  Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation. 2003;107(12):1664-1670. doi:10.1161\/01.CIR.0000057979.36322.88"},{"issue":"24","key":"ref7","series-title":"Circulation","first-page":"3050","article-title":"Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload","volume":"109","author":"McMullen JR","year":"2004","unstructured":"McMullen JR, Sherwood MC, Tarnavski O,  Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation. 2004;109(24):3050-3055. doi:10.1161\/01.CIR.0000130641.08705.45"},{"issue":"8","key":"ref8","series-title":"J Hypertens","first-page":"1663","article-title":"Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis","volume":"24","author":"Gao XM","year":"2006","unstructured":"Gao XM, Wong G, Wang B,  Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens. 2006;24(8):1663-1670. doi:10.1097\/01.hjh.0000239304.01496.83"},{"issue":"3","key":"ref9","series-title":"J Clin Invest","first-page":"1026","article-title":"Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation","volume":"121","author":"Marin TM","year":"2011","unstructured":"Marin TM, Keith K, Davies B,  Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest. 2011;121(3):1026-1043. doi:10.1172\/JCI44972"},{"issue":"2","key":"ref10","series-title":"Am J Kidney Dis","first-page":"324","article-title":"Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial","volume":"52","author":"Paoletti E","year":"2008","unstructured":"Paoletti E, Amidone M, Cassottana P, Gherzi M, Marsano L, Cannella G. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. Am J Kidney Dis. 2008;52(2):324-330. doi:10.1053\/j.ajkd.2008.04.018"},{"issue":"2","key":"ref11","series-title":"Cell","first-page":"274","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante M","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-293. doi:10.1016\/j.cell.2012.03.017"},{"issue":"7","key":"ref12","series-title":"J Gerontol A Biol Sci Med Sci","first-page":"841","article-title":"Rapamycin: an inhibiTOR of aging emerges from the soil of Easter Island","volume":"71","author":"Arriola Apelo SI","year":"2016","unstructured":"Arriola Apelo SI, Lamming DW. Rapamycin: an inhibiTOR of aging emerges from the soil of Easter Island. J Gerontol A Biol Sci Med Sci. 2016;71(7):841-849. doi:10.1093\/gerona\/glw090"},{"issue":"7","key":"ref13","series-title":"J Gerontol A Biol Sci Med Sci","first-page":"876","article-title":"Intermittent administration of rapamycin extends the life span of female C57BL\/6J mice","volume":"71","author":"Arriola Apelo SI","year":"2016","unstructured":"Arriola Apelo SI, Pumper CP, Baar EL, Cummings NE, Lamming DW. Intermittent administration of rapamycin extends the life span of female C57BL\/6J mice. J Gerontol A Biol Sci Med Sci. 2016;71(7):876-881. doi:10.1093\/gerona\/glw064"},{"issue":"1","key":"ref14","series-title":"Aging Cell","first-page":"28","article-title":"Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system","volume":"15","author":"Arriola Apelo SI","year":"2016","unstructured":"Arriola Apelo SI, Neuman JC, Baar EL,  Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system. Aging Cell. 2016;15(1):28-38. doi:10.1111\/acel.12405"},{"issue":"2","key":"ref15","series-title":"Geroscience","first-page":"117","article-title":"A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs","volume":"39","author":"Urfer SR","year":"2017","unstructured":"Urfer SR, Kaeberlein TL, Mailheau S,  A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. Geroscience. 2017;39(2):117-127. doi:10.1007\/s11357-017-9972-z"},{"issue":"10","key":"ref16","series-title":"J Am Vet Med Assoc","first-page":"1188","article-title":"Development and evaluation of a questionnaire for assessment of health-related quality of life in cats with cardiac disease","volume":"240","author":"Freeman LM","year":"2012","unstructured":"Freeman LM, Rush JE, Oyama MA,  Development and evaluation of a questionnaire for assessment of health-related quality of life in cats with cardiac disease. J Am Vet Med Assoc. 2012;240(10):1188-1193. doi:10.2460\/javma.240.10.1188"},{"key":"ref17","series-title":"Tolerance of Rapamycin in Cats","article-title":"TriviumVet","author":"Langford V","year":"2020","unstructured":"Langford V. TriviumVet. Tolerance of Rapamycin in Cats. Kingfisher International Inc; 2020."},{"issue":"2","key":"ref18","series-title":"Vet Comp Oncol","first-page":"311","article-title":"Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats","volume":"19","author":"LeBlanc AK","year":"2021","unstructured":"LeBlanc AK, Atherton M, Bentley RT,  Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Vet Comp Oncol. 2021;19(2):311-352. doi:10.1111\/vco.12677"},{"issue":"1","key":"ref19","series-title":"J Vet Intern Med","first-page":"111","article-title":"Two-dimensional echocardiographic assessment of the feline left atrium","volume":"20","author":"Abbott JA","year":"2006","unstructured":"Abbott JA, MacLean HN. Two-dimensional echocardiographic assessment of the feline left atrium. J Vet Intern Med. 2006;20(1):111-119. doi:10.1892\/0891-6640(2006)20[111:teaotf]2.0.co;2"},{"key":"ref20","series-title":"Tierarztl Prax Ausg K Kleintiere Heimtiere","first-page":"331","article-title":"Echocardiographic measurement of left atrial dimension in healthy cats and cats with left ventricular hypertrophy","volume":"34","author":"Maerz I","year":"2006","unstructured":"Maerz I, Schober K, Oechtering G. Echocardiographic measurement of left atrial dimension in healthy cats and cats with left ventricular hypertrophy. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2006;34:331."},{"issue":"4","key":"ref21","series-title":"Cardiovasc Drugs Ther","first-page":"257","article-title":"The mTOR\/p70S6K signal transduction pathway plays a role in cardiac hypertrophy and influences expression of myosin heavy chain genes in vivo","volume":"18","author":"Boluyt MO","year":"2004","unstructured":"Boluyt MO, Li ZB, Loyd AM, Scalia AF, Cirrincione GM, Jackson RR. The mTOR\/p70S6K signal transduction pathway plays a role in cardiac hypertrophy and influences expression of myosin heavy chain genes in vivo. Cardiovasc Drugs Ther. 2004;18(4):257-267. doi:10.1023\/B:CARD.0000041245.61136.56"},{"issue":"38","key":"ref22","series-title":"J Biol Chem","first-page":"24610","article-title":"Differential activation of p70 and p85 S6 kinase isoforms during cardiac hypertrophy in the adult mammal","volume":"273","author":"Laser M","year":"1998","unstructured":"Laser M, Kasi VS, Hamawaki M, Cooper G IV, Kerr CM, Kuppuswamy D. Differential activation of p70 and p85 S6 kinase isoforms during cardiac hypertrophy in the adult mammal. J Biol Chem. 1998;273(38):24610-24619. doi:10.1074\/jbc.273.38.24610"},{"issue":"4","key":"ref23","series-title":"Am J Physiol","first-page":"H1273","article-title":"Role of load in regulating eIF-4F complex formation in adult feline cardiocytes","volume":"277","author":"Tuxworth WJ Jr","year":"1999","unstructured":"Tuxworth WJ Jr, Wada H, Ishibashi Y, McDermott PJ. Role of load in regulating eIF-4F complex formation in adult feline cardiocytes. Am J Physiol. 1999;277(4):H1273-H1282. doi:10.1152\/ajpheart.1999.277.4.H1273"},{"issue":"9","key":"ref24","series-title":"Cell Signal","first-page":"1904","article-title":"mTOR complex 2 mediates Akt phosphorylation that requires PKC\u03b5 in adult cardiac muscle cells","volume":"25","author":"Moschella PC","year":"2013","unstructured":"Moschella PC, McKillop J, Pleasant DL, Harston RK, Balasubramanian S, Kuppuswamy D. mTOR complex 2 mediates Akt phosphorylation that requires PKC\u03b5 in adult cardiac muscle cells. Cell Signal. 2013;25(9):1904-1912. doi:10.1016\/j.cellsig.2013.05.001"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/261\/11\/javma.23.04.0187.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/261\/11\/javma.23.04.0187.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/261\/11\/javma.23.04.0187.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T13:04:20Z","timestamp":1741352660000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/261\/11\/javma.23.04.0187.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":24,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.2460\/javma.23.04.0187","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}